An Explorative Trial Evaluating the Effect of LEO 32731 Cream 20 mg/g in Adults With Mild to Moderate Atopic Dermatitis (AD)
Latest Information Update: 05 May 2017
At a glance
- Drugs Orismilast (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 13 May 2016 Status changed from active, no longer recruiting to completed.
- 17 Feb 2016 Planned end date changed from 1 Jan 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 17 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.